http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 16:01:34 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Exicure+receives+Nasdaq+delinquency+notice%2C+files+delayed+quarterly+report/26583313.html <p>Exicure Inc. (NASDAQ: XCUR) received a delinquency notification from Nasdaq on May 28, 2026, for failing to file its quarterly report on time, according to a company statement.</p><p>The Listing Qualifications Department of The Nasdaq Stock Market notified Exicure that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-Q for the three months ended March 31, 2026.</p><p>The company attributed the delay to additional time required following changes in its financial reporting personnel and related filing procedures.</p><p>Exicure filed its quarterly report with the Securities and Exchange Commission on May 29, 2026, and http://www.streetinsider.com/Corporate+News/Exicure+receives+Nasdaq+delinquency+notice%2C+files+delayed+quarterly+report/26583313.html Mon, 01 Jun 2026 16:01:34 -0400 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html <p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (Nasdaq: XCUR, the “Company”) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p> <p align="justify">The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html Mon, 01 Jun 2026 16:00:00 -0400 A.50216776 O.29783969 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html <p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (Nasdaq: XCUR, the “Company”) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p> <p align="justify">The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html Mon, 01 Jun 2026 16:00:00 -0400 A.50216776 O.29783969 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html <p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (Nasdaq: XCUR, the “Company”) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p> <p align="justify">The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html Mon, 01 Jun 2026 16:00:00 -0400 A.50216776 O.29783969 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html <p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (Nasdaq: XCUR, the “Company”) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p> <p align="justify">The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html Mon, 01 Jun 2026 16:00:00 -0400 A.50216776 O.29783969 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html <p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (Nasdaq: XCUR, the “Company”) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p> <p align="justify">The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html Mon, 01 Jun 2026 16:00:00 -0400 A.50216776 O.29783969 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html <p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (Nasdaq: XCUR, the “Company”) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p> <p align="justify">The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html Mon, 01 Jun 2026 16:00:00 -0400 A.50216776 O.29783969 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html <p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (Nasdaq: XCUR, the “Company”) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p> <p align="justify">The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html Mon, 01 Jun 2026 16:00:00 -0400 A.50216776 O.29783969 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html <p align="justify">REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- <strong> Exicure, Inc. (Nasdaq: XCUR, the “Company”) </strong>announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.</p> <p align="justify">The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Receipt+of+Nasdaq+Delinquency+Notice+and+Filing+of+Form+10-Q/26583281.html Mon, 01 Jun 2026 16:00:00 -0400 A.50216776 O.29783969 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+01/26583056.html si-local-file:///var/storage/secattach/20260601/26583056.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+01/26583056.html Mon, 01 Jun 2026 15:30:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+01/26583056.html si-local-file:///var/storage/secattach/20260601/26583056.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+01/26583056.html Mon, 01 Jun 2026 15:30:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++EXICURE%2C+INC.+++++++++++++For%3A+Mar+31/26573678.html si-local-file:///var/storage/secattach/20260529/26573678.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++EXICURE%2C+INC.+++++++++++++For%3A+Mar+31/26573678.html Fri, 29 May 2026 14:10:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++EXICURE%2C+INC.+++++++++++++For%3A+Mar+31/26573678.html si-local-file:///var/storage/secattach/20260529/26573678.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++EXICURE%2C+INC.+++++++++++++For%3A+Mar+31/26573678.html Fri, 29 May 2026 14:10:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++EXICURE%2C+INC.+++++++++++++For%3A+Mar+31/26504711.html si-local-file:///var/storage/secattach/20260515/26504711.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++EXICURE%2C+INC.+++++++++++++For%3A+Mar+31/26504711.html Fri, 15 May 2026 16:02:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++EXICURE%2C+INC.+++++++++++++For%3A+Mar+31/26504711.html si-local-file:///var/storage/secattach/20260515/26504711.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-Q++++EXICURE%2C+INC.+++++++++++++For%3A+Mar+31/26504711.html Fri, 15 May 2026 16:02:00 -0400 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html <p>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.</p> <p>The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.</p> <p>Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.</p> http://www.streetinsider.com/Press+Releases/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html Wed, 22 Apr 2026 19:54:00 -0400 A.50114135 O.05723586 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html <p>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.</p> <p>The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.</p> <p>Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.</p> http://www.streetinsider.com/Press+Releases/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html Wed, 22 Apr 2026 19:54:00 -0400 A.50114135 O.05723586 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html <p>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.</p> <p>The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.</p> <p>Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.</p> http://www.streetinsider.com/Press+Releases/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html Wed, 22 Apr 2026 19:54:00 -0400 A.50114135 O.05723586 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html <p>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.</p> <p>The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.</p> <p>Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.</p> http://www.streetinsider.com/Press+Releases/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html Wed, 22 Apr 2026 19:54:00 -0400 A.50114135 O.05723586 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html <p>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.</p> <p>The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.</p> <p>Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.</p> http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html Wed, 22 Apr 2026 19:54:00 -0400 A.50114135 O.05723586 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html <p>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.</p> <p>The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.</p> <p>Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.</p> http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html Wed, 22 Apr 2026 19:54:00 -0400 A.50114135 O.05723586 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html <p>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.</p> <p>The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.</p> <p>Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.</p> http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html Wed, 22 Apr 2026 19:54:00 -0400 A.50114135 O.05723586 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html <p>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.</p> <p>The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.</p> <p>Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.</p> http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Co-Development+Agreement+with+Adbiotech+for+Burixafor+%28GPC-100%29/26352953.html Wed, 22 Apr 2026 19:54:00 -0400 A.50114135 O.05723586 O.31702753 XCUR http://www.streetinsider.com/Board+Changes/Exicure+appoints+Yoontae+Han+to+board+and+audit+committee/26300222.html <p>Exicure Inc. (NASDAQ: XCUR) announced the appointment of Yoontae Han as a director, effective April 8, 2026. The board also named Han to the company's audit committee.</p><p>The appointment is effective until a successor is elected and qualified or until Han's death, resignation or removal. Han will receive an annual retainer of $20,000 for his board service.</p><p>The company also appointed Dongho Lee, currently an audit committee member, as chair of the audit committee. Exicure plans to enter into an indemnification agreement with Han using the same form as other directors, previously filed with the Securities and Exchange Commission in October 2017.</p><p>The http://www.streetinsider.com/Board+Changes/Exicure+appoints+Yoontae+Han+to+board+and+audit+committee/26300222.html Fri, 10 Apr 2026 16:19:41 -0400 XCUR http://www.streetinsider.com/Corporate+News/Exicure+appoints+Yoontae+Han+to+board+and+audit+committee/26300222.html <p>Exicure Inc. (NASDAQ: XCUR) announced the appointment of Yoontae Han as a director, effective April 8, 2026. The board also named Han to the company's audit committee.</p><p>The appointment is effective until a successor is elected and qualified or until Han's death, resignation or removal. Han will receive an annual retainer of $20,000 for his board service.</p><p>The company also appointed Dongho Lee, currently an audit committee member, as chair of the audit committee. Exicure plans to enter into an indemnification agreement with Han using the same form as other directors, previously filed with the Securities and Exchange Commission in October 2017.</p><p>The http://www.streetinsider.com/Corporate+News/Exicure+appoints+Yoontae+Han+to+board+and+audit+committee/26300222.html Fri, 10 Apr 2026 16:19:41 -0400 XCUR